Allograft Mitral Valve Replacement
Mark D. Plunkett, Linda M. Bond, and Dale M. Geiss
Allograft valves have been used in cardiac valve replacement for over 40 years. Early failures of allograft mitral valve replacement (AMVR) were attributed to inadequate allograft preservation or unsuccessful implantation techniques. Due to an improved understanding of mitral valve function gained from experience in mitral valve reconstruction, improved imaging techniques for preoperative assessment, and improved methods of allograft preservation, there has been a resurgence of interest in AMVR. The use of bioprosthetic valves in children and young adults is characterized by reduced durability and early valve failure. With the use of mechanical valves, there is a significant long-term risk of morbidity and mortality resulting from thrombosis or hemorrhagic complications from anticoagulation. Additionally, anticoagulation is often difficult to manage in children. The advantages of using allograft mitral valves include the avoidance of anticoagulation and the preservation of the subvalvar apparatus and its role in ventricular function. At our institution, successful early results with AMVR have been obtained in eight children and young adults with previous atrioventricular septal defects, previous placement of mitral valve prostheses, rheumatic valvular disease, and bacterial endocarditis. Our early results and those of others are encouraging for the continued use of AMVR in children and young adults. Long-term follow-up will be necessary to assess the durability and function of these allograft mitral valves.
Key words: Allograft, mitral valve.
From the Division of Cardiovascular and Thoracic Surgery, University of Illinois College of Medicine, and Children's Hospital of Illinois, St Francis Medical Center, Peoria, IL.
Address reprint requests to Mark D. Plunkett, MD, Illinois Cardiac Surgery Associates, SC, 515 NE Glen Oak, Suite 202, Peoria, IL 61603.
© 1999 by W.B. Saunders Company
|
